Supriya Lifescience has reported a reduction in revenue and profitability during the first quarter of FY26, owing mostly to planned repairs and maintenance at its Lote production facility. The Mumbai-based active pharmaceutical ingredient (API) manufacturer, which exports to over 86 countries, reported unaudited financial figures on Monday. 

The company's consolidated revenue for Q1FY26 was ₹145.07 crore, down 9.7% from ₹160.63 crore in the same quarter of the prior year. Earnings before interest, tax, depreciation, and amortisation (EBITDA) decreased to ₹51.7 crore from ₹62.54 crore, with margins decreasing to 35.6% from 38.9%. In Q1FY25, profit after tax (PAT) was ₹44.64 crore, up from ₹34.79 crore in Q1FY25. The increase resulted in a PAT margin of 24%, compared to 27.8% the previous year. Earnings per share decreased to ₹4.3, from ₹5.5, according to a media statement. 

Satish Wagh, Chairman and Managing Director, stated that the reduction was due to production campaign delays caused by "essential repair and maintenance at our Lote facility." He further stated that the changes were "critical to improving the efficiency of our older blocks and enabling full use of Module E for upcoming product launches." 

Despite the overall reduction, the anaesthesia segment emerged as a growth driver, accounting for 53% of quarterly revenues, up from 45% the previous year. Geographically, the European market accounted for 41% of revenues, up from 34% in Q1FY25, indicating a shift to regulated markets. 

The company reported higher capacity utilization—up to 76% in Q1 FY26 from 70% in FY25. It has also purchased three land lots near current operations to facilitate future growth. Wagh stated that the company remains focused on improving backward integration and regulatory market contributions, which has helped maintain EBITDA margins above 35% despite lower revenues. 

Looking ahead, Supriya Lifescience expects performance to stabilise in the second half of fiscal year 26. "With the Ambernath site progressing towards commercial production in Q4, a strong pipeline of 3-4 product launches in FY26, and healthy demand across key therapeutic areas, we expect the second half to recover the delays from H1," Wagh pointed out. He restated the company's target of reaching 20% growth and generating ₹1,000 crore in revenue by FY27. 

The Q1 statistics show the balancing act that API manufacturers must perform between preserving plant efficiency and supporting revenue growth, particularly when global demand and regulatory requirements place a heavy burden on operations.